Public Reporting The National Performance Management Programme
TaPasefika entered the PHO Performance Management Programme in January 2006.
It is important to note population variations for the context in which TaPasefika and its providers work:
|
% People by Ethnicity |
TaPasefika |
CMDHB |
National |
|
NZ Maori |
13% |
17% |
15% |
|
Pacific Peoples |
68% |
21% |
7% |
|
European/Other |
19% |
62% |
78% |
Achievement of indicators for the July 2008-June 2009 year was slightly compromised by the Swine Flu Pandemic that hit TaPasefika in the last quarter of 2009. This was particularly the case for Cervical smears, mammography and under two immunisations. Please note that TaPasefika’s Under Two Immunisation for high needs is 65.10%, above the CMDHB average of 57.89% for 2009.
All other indicators were achieved; with CVD and Diabetes indicators achieving performance well above local and national performance levels.
|
|
|
|
|
|
|
|
|
|
- |
28.08 |
32.55
NZ 23.04
DHB 26.34 |
32.55 |
4.47% |
P |
|
|
- |
32.44 |
40.98
NZ 21.52
DHB 36.66 |
40.00 |
8.54% |
P |
|
|
- |
139.04 |
148.61
NZ 106.02
DHB 128.27 |
90.00 |
9.57% |
P |
|
|
- |
102.39 |
111.63
NZ 56.43
DHB 60.36 |
80.00 |
9.24% |
P |
|
|
35.50
|
52.99
NZ 61.7
DHB 55.29 |
54.98
NZ 63.89
DHB 58.49 |
55.99 |
1.99%
Needed 3% to achieve target |
O |
|
|
29.61
|
44.05
NZ 51.61
DHB 46.47 |
46.34
NZ 55.58
DHB 49.16 |
48.05 |
2.29%
Needed 4% to achieve target |
O |
|
|
34.84 |
52.68
NZ 60.32
DHB 58.9 |
57.04
NZ 65.84
DHB 62.62 |
56.41 |
4.36%
|
P |
|
|
34.94 |
52.89
NZ 60.32
DHB 58.9 |
57.89
NZ 63.28
DHB 62.04 |
55.77 |
5% |
P |
|
|
51.41 |
68.42
NZ 64.57
DHB 43.67 |
65.10
NZ 69.13
DHB 57.89 |
72.21 |
-3.32%
Needed 3.79% to achieve target |
O |
|
|
89.61 |
98.15
NZ 98.84
DHB 98.45 |
97.34
NZ 99.08
DHB 98.8 |
>=99.5 |
0% |
P |
|
|
|
1.14
NZ 1.1
DHB 1.22 |
1.37
NZ 1.11
DHB 1.23 |
>=1 |
0% |
P |
|
|
139.37 |
104.78
NZ 85.51
DHB 103.42 |
103.76
NZ 80.21
DHB 101.36 |
106.0 |
-1.02% |
P |
|
|
77.01 |
95.56
NZ 94.31
DHB 92.54 |
71.01
NZ 88.34
DHB 87.16 |
<=100 |
-24.55% |
P |
2009 BPAC PHO Reports
Best Practice Reporting indicate: To prevent cardiovascular mortality and morbidity, risk assessment should be performed every 5years to detect remediable factors. A higher proportion of TaPasefika patients have their cardiovascular risk assessed than the national population.
|
% Male Patients had Lipids Tested |
TaPasefika |
National |
|
NZ Maori (35-44y) |
16.8% |
14.0% |
|
Pacific Peoples (35-44y) |
21.7% |
19.8% |
|
European/Other (45-54y) |
46.7% |
33.1% |
A higher proportion of TaPasefika patients have high cholesterol treated with a statin.
|
% Male Patients Dispensed Statins |
TaPasefika |
National |
|
NZ Maori (35-44y) |
6.1% |
4.4% |
|
Pacific Peoples (35-44y) |
10.9% |
6.8% |
|
European/Other (45-54y) |
30.2% |
13.3% |
People with diabetes are having their diabetes management adequately monitored.
|
% Patients on Oral Antidiabetic Medication had HbA1C tested (35years+) |
TaPasefika |
National |
|
NZ Maori |
91.5% |
85.4% |
|
Pacific Peoples |
92.3% |
88.3% |
|
European/Other |
93.6% |
86.8% |
People with diabetes are having their kidney function adequately monitored.
|
|
TaPasefika |
CMDHB |
National |
|
% Patients on Oral Antidiabetic Medication had Annual Creatinine Blood Test (30-70years) |
92% |
88% |
81% |
|
% Patients on Oral Antidiabetic Medication had Annual Microalbumin Urine Test (30-70years) |
90% |
82% |
73% |
A higher proportion of TaPasefika patients have high blood pressure, left ventricular heart dysfunction, and kidney disease requiring ACE inihibitors / Angiotension Receptor Blockers medication.
|
% Patients Dispensed ACE/ARB (35years+) |
TaPasefika |
National |
|
NZ Maori |
23.9% |
18.0% |
|
Pacific Peoples |
28.9% |
20.5% |
|
European/Other |
37.3% |
17.4% |
Relative to Pacific patients who make up the majority of enrolees, Maori appear to have the lowest access to testing and prescriptions and European/Other ethnicity patients to have the highest access. This access disparity within TaPasefika has been highlighted with clinical leaders, and will be explored and monitored. |